Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 2 Interventional

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT07428044

Public ClinicalTrials.gov record NCT07428044. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Neoadjuvant Trastuzumab Deruxtecan for Patients With Stage II-III HER2-Amplified or HER2-Mutated Non-Small Cell Lung Cancer (HERCULES)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.

Study identification

NCT ID
NCT07428044
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 2
Enrollment
Not listed

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 13, 2026 (Actual)
Primary completion
Feb 13, 2027 (Estimated)
Completion
Feb 13, 2027 (Estimated)
Last update posted
Oct 20, 2026

2026 – 2027

United States locations

U.S. sites
9
U.S. states
4
U.S. cities
9
Facility City State ZIP Site status
University of Michigan (Data Collection Only) Ann Arbor Michigan 48109 —
Mayo Clinic (Data Collection Only) Rochester Minnesota 55905 —
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey 07920 —
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 —
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 —
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack New York 11725 —
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 —
Memorial Sloan Kettering Cancer Center (All Protocol Activites) New York New York 10065 —
Memorial Sloan Kettering Nassau (Limited Protocol Activites) Rockville Centre New York 11553 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07428044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2026 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07428044 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →